N-myc is a gene whose amplification has been demonstrated in three forms of malignant human tumors-neuroblastoma (23, 28, 39) , retinoblastoma (27) , and small cell carcinoma of the lung (30) . In the absence of amplification, the gene is expressed in a limited variety of cells and tissues (17, 40, 48) , but its function in either normal or malignant cells is not known.
Three points of evidence suggest that N-myc may contribute to tumorigenesis. First, studies on the structure of N-myc have revealed a remarkable kinship with the protooncogene c-myc, which has also been implicated in tumorigenesis (24, 43) . Second, amplification of N-myc in human neuroblastomas occurs principally in rapidly progressing forms of the tumor, as if abundant expression of N-myc might exacerbate the malignant phenotype of the tumor (3). Third, molecular clones of N-myc can cooperate with a mutant version of the proto-oncogene c-Ha-ras to transform embryonic rat cells in culture (41, 47) . These findings suggest that N-myc is an authentic proto-oncogene and that elucidation of its biochemical function may provide insight into the genesis of several different human tumors.
To explore the function of N-myc, we produced rabbit antisera that allowed the identification of two related proteins encoded by the gene. Both proteins bear striking resemblances to the products of c-myc, and their properties suggest that N-myc may be a regulatory gene. Slamon et al. (42) have recently described products of human N-myc that are apparently identical to those reported here.
MATERIALS AND METHODS
Cells. The human colonic apudoma cell line COL0320-HSR, the three neuroblastoma lines Kelly, IMR-32, and NMB, the retinoblastoma line Y79, and the cervical carcinoma line HeLa were all obtained from the American Type Culture Collection. Human skin fibroblasts and rat embryo cultures were obtained from the University of California at San Francisco Cell Culture Facility. The rat embryo cell line transformed by cotransfection with the oncogenes ras and N-myc has been described previously (11) . * Corresponding author.
Peptide coupling and immunization. Three peptides were synthesized according to the human N-myc nucleotide sequence and supplied by Sequemat, Inc. Peptide R (residues 104 to 113) and G (residues 44 to 58) have complete homology with regions in the human c-myc protein, whereas peptide Y (residues 23 to 34) was unique for N-myc. The peptides were coupled to tuberculin-purified protein derivative (TPPD) by glutaraldehyde (45) . The TPPD was dialyzed to remove glutaraldehyde and peptide. Each coupled peptide was injected subcutaneously into three rabbits (female New Zealand White, 2 to 4 kg). Rabbits were immunized on the following schedule: 200 ,ug of peptide-coupled TPPD in complete Freund adjuvant on day 0; 200 ,ug in incomplete Freund adjuvant subcutaneously on day 14; and 200 ,ug with 4 mg of alum subcutaneously on day 21. After the initial course of injections, rabbits were boosted with 200 ,ug of peptide-coupled TPPD with 4 mg of alum at four 1-week intervals and bled 1 to 2 weeks following injection.
Cell labeling, immunoprecipitation, and electrophoresis. Immunoprecipitation from labeled cell lysates was performed as described previously (36 (36) . For competitive inhibition of antibody precipitation (blocking) experiments, 20 ,ug of peptide per ,ul of sera were incubated together for 30 min at 4°C and then used directly in the immunoprecipitation assay. The released proteins were electrophoresed on discontinuous 10% SDS-polyacrylamide gels and fluorographed (36) .
S. aureus V8 protease mapping. The proteins of interest were solubilized, immunoprecipitated, and electrophoresed as described above. The gel was dried down and exposed for autoradiography. The bands of interest were identified and 4450 on July 4, 2017 by guest http://mcb.asm.org/ Downloaded from cut out, and the proteins were then subjected to partial V8 proteolytic analysis as described by Cleveland et al. (5) .
In vitro synthesis of N-myc-specific mRNA and proteins. A 1.6-kilobase-pair XbaI-EcoRI fragment from a human N-myc cDNA clone was inserted into the corresponding restriction sites of the polylinker in vector pSP64, giving rise to the construct pcN64RX (see Fig. 4A ). The EcoRI site of the cDNA that was used in this construction is artificial, having been introduced during the cDNA cloning procedure. N-myc RNA was synthesized from pcN64RX as follows. A 50-RI reaction containing 2 ,ug of plasmid (linearized at the EcoRI site), 40 mM Tris hydrochloride (pH 7.5), 6 mM MgC92, 2 mM spermidine, 10 mM NaCl, 10 mM dithiothreitol (DTT), 50 U of RNasin (Promega Biotec), 500 ,uM each ATP, CTP, UTP, and GTP, and 10 U of SP6 RNA polymerase (Promega Biotec) was incubated at 37°C for 90 min. The reaction mixture was then treated with 2 U of pancreatic DNase at 27°C for 15 min, followed by equal-volume extractions, once with phenol and twice with chloroform. The RNA was then precipitated by ethanol in the presence of 2 M ammonium acetate. The yield of RNA was approximately 10 ,ug. The in vitro-transcribed N-myc RNA was then translated in a rabbit reticulocyte lysate (Promega Biotec), and the translational products were analyzed on a 10% SDS-polyacrylamide gel. Subcellular fractionation. Approximately 2 x 107 cells were labeled as described above and then fractionated by a method similar to that described by Klempnauer et al. (21) . Cells were washed twice in ice-cold hypotonic buffer containing 5 mM KCI, 1 mM MgCl2, and 25 mM Tris hydrochloride (pH 7.4) and then incubated in that buffer for 15 min. Then an equal volume of hypotonic buffer containing 1% NP40 was added, and the cells were incubated for a further 5 min. The nuclei were separated from the cytoplasmic fraction by centrifugation at 1,000 x g for 5 min and then washed twice in hypotonic buffer plus 0.5% NP40 before solubilization in lysis buffer. The wash fractions were combined with the cytoplasmic fraction and then adjusted to the same salt and detergent concentration as the nuclear fraction. All fractions were then analyzed by immunoprecipitation as described above.
DNA-cellulose chromatography. The DNA-binding experiment was performed as described elsewhere (34) . Cells that had been labeled with 32p, were washed with Tris-saline and lysed in 200 pul of buffer A (10 mM Tris hydrochloride, pH 8.0, 1 mM MgCl2, 0.5% NP40, 0.45 M NaCl). The lysate was then clarified by centrifugation at 10,000 x g for 10 min at 4°C. The supernatant was removed and immediately diluted 10-fold with loading buffer (10 mM potassium phosphate, pH 6.2, 1 mM MgCl2, 0.5% NP40, 1 mM DIT, 10% glycerol) without salt and adjusted to pH 6.2 by the addition of 0.01 M HCl. The extract was then loaded onto a column of single-or double-stranded calf thymus DNA-cellulose (bed volume approximately 1 ml; P-L Biochemicals, Inc., Milwaukee, Wis.) which had been equilibrated in loading buffer with 50 mM NaCl. The column was then washed with 5 bed volumes of loading buffer to remove any unbound protein. Bound protein was removed by washing the column with elution buffer (10 mM Tris hydrochloride, pH 8.0, 1 mM DTT, and increasing concentrations of NaCl). Samples of the flowthrough and gradient fractions were analyzed by immunoprecipitation.
RESULTS
Identification of proteins encoded by N-myc. We used three synthetic oligopeptides as antigens (Materials and Methods).
Two of these represent regions that are shared between the proteins encoded by c-myc and N-myc; the third is unique to N-myc. All are located in the amino-terminal domain of the N-myc protein, the only portion of the protein for which we had deduced the amino acid sequence at the time the choices of antigens were made. When coupled to carrier protein, all three oligopeptides elicited rabbit antibodies that reacted specifically with the homologous immunogen in enzymelinked immunosorbent assays. Only the antiserum induced by the unique peptide immunoprecipitated cellular proteins that might be encoded by N-myc (data not shown). We designated this antiserum Y3 and proceeded to characterize its reactivity in detail.
The N-myc gene is expressed at very low levels or not at all in most established lines of human cells that have been examined (22, 40) . We therefore performed our preliminary tests with the neuroblastoma cell line Kelly, in which N-myc RNA is abundant by virtue of a 200-fold amplification of the gene (40) . When reacted with extracts of Kelly cells, the Y3 antiserum immunoprecipitated two proteins with molecular weights of 65,000 and 67,000 (Fig. 1A , lane 4), whose resolution is better illustrated in Fig. 1C . Precipitation of both proteins could be blocked by competition with the peptide used to induce the antisera (Fig. 1A , lane 3). Since both proteins were phosphorylated and since both were encoded by N-myc (see below), we designated them
We examined a series of cell lines to determine whether the amounts of the putative N-myc proteins reflected the previously determined abundance of N-myc RNA (Fig. 1B , lanes 1 to 10). We used three cell lines that display amplification of N-myc (the neuroblastoma lines IMR-32 and NMB and the retinoblastoma line Y79) and two sorts of cells in which N-myc is not amplified (HeLa cells and human skin fibroblasts). All of the cell lines with amplification of N-myc contained readily detectable pp65/67NmYc, whereas no Nmyc protein could be detected in the cells with diploid copies of N-myc. These results exemplify our subsequent experience with numerous human cell lines: N-myc protein was detectable only in cells with amplification of the gene; amplification of N-myc had no effect on the molecular weights of the gene products; and in no instance were the relative amounts of pp65 and pp67 changed (data not shown).
We made a preliminary comparison with products of c-myc by immunoprecipitating pp62/66c-myc(human) from the cell line COL0320 (Fig. 1A , lane 2) with a previously characterized antiserum (35) . The results demonstrated three similarities between the products of c-myc and N-myc. (i) The products of the two genes had similar molecular weights. (ii) The proteins ran at anomalous positions in SDS-polyacrylamide gels: the predicted molecular weights of the two gene products predicted from nucleotide sequencing should be 48,000 (c-myc) (6) and 49,000 (N-myc) (24, 43) . (iii) Two forms of product from each gene could be detected.
The peptide against which our antiserum was raised has no homology with c-myc, and no cross-reactivity was observed in immunoprecipitations with cells containing high levels of c-myc protein (data not shown). Similarly, our previously described antisera directed against the products of c-myc failed to react with the proteins allegedly encoded by N-myc.
Authentication of the N-myc products by gene transfer. It is possible to establish transformed cells from primary rat embryo cells after cotransfection with the N-myc and ras genes (41, 47) . We made use of cells transformed in this way to show that introduction of N-myc into a cell not previously VOL. 6, 1986 on July 4, 2017 by guest http://mcb.asm.org/ Downloaded from expressing the gene results in the production of pp65/ 67N-myc(human)* We used cell lines transfected with c-Ha-ras (EJ) in combination with a construction containing the two coding exons of N-myc linked to the promoter-enhancer of Moloney murine leukemia virus (41) . The Y3 antiserum did not precipitate proteins resembling the products of N-myc from rat embryo cells (Fig. 2, lane 2) . Thus, either the antiserum does not react with the rat N-myc protein or the level of that protein in the cells is so low it is undetectable. (The latter possibility is likely to be correct, since N-myc 2) RNA cannot be detected in cultures of rat embryo cells [41] .) With the cell lines cotransfected with N-myc and ras, however, pp65 and pp67 were specifically precipitated and found to comigrate with the proteins detected in Kelly cells (Fig. 2, lanes 4 and 6) . We conclude that pp65 and pp67 are probably encoded by human N-myc. N-myc products generated by translation in vitro. We used translation in vitro to authenticate further the genetic origin of pp65 and pp67 and to address the genesis of the two forms of the protein. The SP6 bacteriophage promoter was used to transcribe a cDNA containing the entire coding unit of N-myc (Fig. 3A) . Translation of the resulting RNA produced two proteins with electrophoretic mobilities identical to those of the candidate products of N-myc and two smaller proteins with molecular weights of ca. 55,000 (Fig. 3B, lane  2) . To determine whether the pp65/67 synthesized in vivo was related to the pp65/67 seen in vitro, we carried out partial proteolytic mapping with S. aureus V8 protease. pp65 and pp67 made in vivo gave maps identical to those of the pp65 and pp67 synthesized in vitro (Fig. 3C, lanes 1 through   4) .
We conclude that we have identified authentic products of N-myc. The two larger proteins (pp65 and pp67) must arise from the same mRNA and the same reading frame, perhaps by virtue of modification subsequent to translation: the cDNA contains only one reading frame capable of encoding these proteins, and splicing to give different mRNAs is unlikely to occur in the transcriptional reaction with the SP6 promoter. The two smaller proteins produced in abundance in vitro have not been found in cells (data not shown). They could be the products of either proteolytic cleavage or translational initiation within the reading frame.
Products of N-myc(human) are unstable phosphoproteins.
Labeling cells with 32P; revealed that both forms of the protein encoded by N-myc were phosphorylated (Fig. 4, protease, and electrophoresed on a 14% polyacrylamide gel as described in Materials and Methods. Lanes: 1, in vivo p65; 2, in vitro p65; 3, in vivo p67; 4, in vitro p67.
was found in the nuclear fraction (Fig. 6) . We attempted to extend these observations by the use of immunofluorescence microscopy but were unable to obtain a persuasive signal, perhaps because the N-myc proteins were not sufficiently abundant in any of the cells we examined (data not shown).
We have encountered similar difficulties with the products of c-myc with cells in which the abundance of c-myc protein resembled that of N-myc protein in the cells examined here.
N-myc protein binds to DNA. The viral and cellular myc gene products bind to both single-and double-stranded DNA (9, 10, 32, 46) . We therefore tested the N-myc product for similar capability. The DNA binding was performed by DNA-cellulose chromatography as previously described for simian virus 40 large tumor antigen (34) . A column containing cellulose without bound DNA did not retain pp65/ 67N-myc(human) (data not shown). By contrast, columns containing cellulose linked to calf thymus single-or doublestranded DNA retained a high proportion of pp65/ 67N-myc(human) (Fig. 7A and B) . The N-myc protein could be eluted with NaCl concentrations ranging from 0.3 to 2.0 M (Fig. 7A and B) . When the material present in the column flowthrough was rechromatographed, most of the N-myc protein bound to the DNA, suggesting that we exceeded the capacity of the column in the initial fractionation. We conclude that the N-myc proteins can bind to DNA, but the specificity and mechanism of that binding remain to be evaluated.
DISCUSSION
Identification of the proteins encoded by human N-myc. We used an oligopeptide as an antigen to obtain an antiserum that reacts with the proteins encoded by human N-myc. Two of the peptides tested originally as antigens represented amino acid sequences found in the proteins encoded by both c-myc and N-myc. Neither of these peptides elicited a useful antiserum. The successful immunizations were performed with an oligopeptide that is unique to the N-myc protein. We chose this peptide for use because it contained a small hydrophobic region that in the full N-myc protein is embedded within a large hydrophilic domain. We reasoned that the entire domain was likely to be on the surface of the protein and that the small hydrophobic region might therefore be 1 2
We used pulse-chase analysis to determine the half-lives of pp65/67N myc(human) and explore the relationship of the two proteins. Both forms were labeled and chased in a parallel fashion, demonstrating that neither protein is a precursor of the other (Fig. 5A) . These data allowed us to determine that the half-lives of pp65 and pp67 are ca. 30 min (Fig. 5B) . This is in remarkable agreement with the half-lives of pp62/ 66c-myc(human) and is in accord with the view that the myc gene family encodes proteins that are regulatory rather than structural elements in the cell (18) .
N-myc proteins are located in the nucleus. The proteins encoded by v-myc and a variety of c-myc genes have been found in the cell nucleus by both biochemical fractionation and immunofluorescence microscopy (1, 2, 9, 15). To determine whether the product of N-myc was similarly located, we prepared subcellular fractions from two cell lines (Kelly and Y79) and assayed the fractions for pp65/67N-mYc(human) by immunoprecipitation. When cells were lysed by hypotonic shock and then fractionated, more than 95% of the pp65/67 From these data, we conclude that our antisera recognize authentic products of human N-myc. Slamon et al. (42) have also identified products of human N-myc with antisera that were raised against antigen synthesized in bacteria and that reacted with proteins encoded by both N-myc and c-myc.
The products of N-myc in cells have always appeared as two proteins, with apparent molecular weights of 65,000 and 67,000. By contrast, the nucleotide sequence of N-myc encodes a protein with a calculated molecular weight of 49,000 (24, 43) . A similar size anomaly has been observed for the products of c-myc (16, 31, 36) . No effort to explain this anomaly by a modification subsequent to translation has succeeded. Instead, it appears likely that the chemical compositions of c-myc and N-myc proteins affect their mobilities during electrophoresis through polyacrylamide.
How do the two forms of c-myc and N-myc proteins arise? Previous efforts to attribute the two c-myc proteins to different mRNAs have now been refuted (31) . We are similarly certain that the two forms of N-myc protein are produced from a single mRNA because transcription of N-myc in vitro, under circumstances in which splicing is unlikely to occur, produces mRNA that can be translated into both forms of the protein. These findings leave the duality of both c-myc and N-myc proteins unexplained, although it is unlikely that they are due to differences in either phosphorylation or glycosylation of the proteins (16, 35 ; present data). myc gene family. Early efforts to isolate human genes related to v-myc revealed a family of genes with several members (12) . Three of these have now been well defined: c-myc (26), L-myc (29) , and N-myc (24, 43) . Each is distinctive, but the three are nevertheless closely related.
The similarities between c-myc and N-myc have been especially well documented. The two genes have remarkably similar topographies and coding domains (24, 43) ; each can cooperate with a mutant version of the proto-oncogene c-Ha-ras to transform embryonic cells in culture (41, 47) ; expression of either gene declines in certain lines of tumor cells when they are induced to differentiate (37, 44) ; and the proteins encoded by the two genes share several prominent biochemical properties and may therefore possess related functions. The two genes differ in their expression, however: c-myc is expressed in a wide variety of cells (14, 33) , whereas expression of N-myc has been detected in only a limited variety of cells and tissues (17, 48 suspect that the two genes serve different physiological purposes, in contrast to the biochemical similarities of their products. N-myc in tumorigenesis. Amplification or abundant expression of N-myc has been reported to be a frequent feature of three human malignancies-neuroblastoma (23, 39) , retinoblastoma (27) , and small cell carcinoma of the lung (30) . These reports were based solely on the analysis of nucleic acids. Here we show that the production of N-myc protein by tumor cells is consonant with the abundance of RNA transcribed from the gene and that amplification of N-myc therefore augments expression of the gene.
What is the significance of amplification and inordinate expression of N-myc in tumor cells? The most provocative clue has come from the finding that amplification of N-myc in human neuroblastomas occurs principally in rapidly progressing forms of the tumor that are resistant to therapy (3). These findings have prompted two suggestions: that inordinate expression of N-myc may exacerbate the malignant phenotype of the tumor, and that amplification of N-myc can be used as a diagnostic and prognostic device. The antisera we have described here should permit these suggestions to be explored in greater detail.
What are the functions of myc genes? The biochemical and physiological functions of the proteins encoded by myc genes are not known. We have three clues to these functions, however, in the form of properties shared by all of the myc proteins studied to date.
First, the proteins are located in the nucleus of both normal and transformed cells (1, 2, 9, 15; present data). The consistency and rapidity with which myc proteins reach the nucleus suggest that the principal site of action for these proteins must be in that organelle. There is disagreement, however, over which compartment within the nucleus contains the site of action: some workers have assigned the proteins to the "nuclear matrix" (10) , and others have questioned this assignment (11). We have not as yet examined this issue in detail for the N-myc proteins, but others have assigned the products of N-myc to the nuclear matrix (42) . Second, the proteins are decidedly unstable, a property 'they share with nuclear proteins encoded by other oncogenes and proto-oncogenes, such as fos (7) and myb (G. Ramsay, unpublished observations). Cellular proteins typically have half-lives that range from 10 h to several days (13) . By contrast, the half-lives of the proteins encoded by fos, myb, and myc are on the order of 30 to 60 min. This property suggests that the proteins are designed to undergo rapid changes in abundance, a conclusion that is further substantiated by the remarkable instability of the mRNA for c-myc (8) .
-Third, the proteins encoded by c-myc and N-myc bind to both single-and double-stranded DNA (9, 10, 31, 46; present data). The products of myb genes have the same property (20, 28; G. Ramsay, unpublished data). The binding of myc protein to DNA is presently regarded as nonspecific (46), and its functional significance is therefore open to question. In addition, it is possible that the binding is mediated by other proteins. We consider this an unlikely possibility because preliminary experiments have shown that N-myc protein still binds to DNA after purification by immunoaffinity chromatography, as is also the case for proteins encoded by c-myc and v-myc (9, 44) . The domain within the proteins responsible for the binding has not been directly identified, although the region that is most conserved between the products of N-myc and c-myc has chemical qualities resembling those of proteins whose functions require interaction with DNA (24, 43) . We conclude that N-myc and its kin are more likely to serve regulatory than structural purposes within the cell. There is only one hint, however, as to what those purposes might be: the claim that c-myc can act in trans to augment transcription from another gene (19) . Our preliminary efforts to demonstrate a similar property for N-myc have failed (N. Hay, personal communication), but the reagents and information described here provide a point of departure from which the function of N-myc can now be explored in detail.
